Xenomics Detects DNA Marker For H. Pylori Bacteria In Urine; Test Results Demonstrate The Ability To Detect And Monitor A Wide Range Of Infectious Conditions.

NEW YORK -- Xenomics, Inc. (OTCBB:XNOM) (FWB:XE7), a developer of next-generation medical DNA diagnostic technologies, today announced that its research scientists have successfully identified DNA sequences of the H. pylori bacteria in the urine of infected patients. The study was performed in collaboration with Dr. Dino Vaira and his colleagues at the University of Bologna in Bologna, Italy.

"This demonstrates the applicability of our non-invasive DNA-based urine test with bacterial pathogens and infectious diseases," said Dr. L. David Tomei, PhD., Xenomic's CEO and co-founder. H. pylori bacteria causes between 80% to 90% of duodenal and gastric ulcers. Many more individuals in the world's population are infected, but have no symptoms and are at increased risk for gastric cancer, mucosal-associated-lymphoid-type (MALT) lymphoma, and other conditions.

Presently, the only tests available for detecting H. pylori are stomach biopsies and blood tests for certain antibodies. "Unfortunately, the latter cannot differentiate between a current infection and the presence of antibodies related to a past infection. Xenomic's urine based DNA diagnostic technology provides a non-invasive and reliable alternative to current practices," commented Dr. Tomei.

Xenomics scientists were the first to discover that DNA from cells located inside the body can cross the kidney barrier and accumulate in the urine, and that through the analysis of easily obtained urine samples from patients, these highly novel Transrenal DNA fragments (Tr-DNA) can provide vital information about a wide range of conditions inside the body, including serious infectious diseases, fetal development during pregnancy, cancer, and numerous other applications.

A particularity important feature of our Tr-DNA diagnostic technology is that it is a true platform technology. Unlike current clinical diagnostic tests that require a variety of often incompatible methods, techniques, and specimens, Xenomics' Tr-DNA test is based upon the isolation and detection of DNA fragments with specific sequences or epigenic modifications.

"The kidney filters DNA fragments from the circulatory system and presents a concentration of Tr-DNA in the urine which also enables our tests to be extremely sensitive and accurate," explained Dr. Tomei. "We believe Tr-DNA technology will foster fundamental improvements in safety, accuracy and functionality of diagnostic testing, currently a $1.5 billion segment of the healthcare industry."

Xenomics intends to develop this platform into a pipeline of potentially groundbreaking commercial medical testing products for the detection and/or monitoring of diverse diseases and health conditions, including prenatal conditions, tuberculosis, HIV/AIDS, cancer, malaria and numerous others.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company's prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more investor-specific information, including daily and historical Company stock quote data, recent news releases and an Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/xenomics. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics' Form SB-2 as filed with the Securities and Exchange Commission on March 15, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.